Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Liver Neoplasms × donafenib × Clear all

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4 Solid Tumor 1 Recurrence 1 Locally Advanced Thyroid Gland Carcinoma 1 Liver Neoplasms 1 Biliary Malignant Tumors 1

Interventions

Bevacizumab 10 pembrolizumab 5 durvalumab 5 atezolizumab 5 lenvatinib 4 tremelimumab 3 fludarabine 3 camrelizumab 3 apatinib 3 Ipilimumab 3 Cyclophosphamide 3 regorafenib 2 Riluzole 2 Radiotherapy 2 Nivolumab 2 Magnetic Resonance Imaging 2 Idarubicin 2 Blood Specimen Collection 2 Biopsy 2 yttrium chloride 1 trastuzumab deruxtecan 1 toripalimab 1 spartalizumab 1 sintilimab 1 pertuzumab 1 fludarabine phosphate 1 ferric carboxymaltose 1 epigallocatechin gallate 1 donafenib 1 brodalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05713994 2025-03-25

CCGLC-001

Tongji Hospital

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡